Nebenwirkungen · Aquipta
AQUIPTA 10 mg tablets AQUIPTA 60 mg tablets · Abschnitt 4.8 · PDF-Seite 5
HOS-149995 · Präparat HOS-100196
Safety was evaluated in 3 852 patients with migraine who received at least one dose of atogepant in clinical studies. Of these, 1 225 patients were exposed to atogepant for prophylaxis daily for at least 6 months and 826 patients were exposed for 12 months. 895 patients were exposed during 24 weeks on an as-needed basis for treatment of acute migraine attacks.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T13:51:04Z · SHA-256 9d42d1f3230d786a522a366a7a9d9a4e1b16d695023c0280fdc3a58f424c9dba · Passage c09775b1207a76365c9c1f29fcbc95c9da91cd0650b4f3846fce94c57a2d8a00 · Zeichen 31–393 im Abschnitt